Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Last Updated: Tuesday, March 25, 2025

Researchers developed the ALL-Hematotoxicity score, which refines an existing predictive model of post CAR T-cell cytopenias to be applicable to B-cell acute lymphoblastic leukemia. The ALL-Hematotoxicity score was associated with severe prolonged neutropenia. It appropriately predicted patients who had more cumulative days of neutropenia, fewer rates of complete response, and shorter median overall survival.

Blood

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Blood

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Science Advances

Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive too

JAMA Network Open

Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis

Blood Advances

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

Blood Advances

Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Blood Advances

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

CAR T-Cell Therapy Resource Center

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Blood

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Science Advances

Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive too

JAMA Network Open

Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis

Blood Advances

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

Blood Advances

Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Blood Advances

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Fast Facts #12: BCMA Targets